{"disease":{"id":"glaucoma","name":"Glaucoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":14},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Neovascular glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"paclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"dichlorophen","indication_name":"Angle-closure glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didroxan","generic_name":"DICHLOROPHEN","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"dichlorophen","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"dichlorophen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didroxan","generic_name":"DICHLOROPHEN","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"dichlorophen","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"dichlorophen","indication_name":"Secondary glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Didroxan","generic_name":"DICHLOROPHEN","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"dichlorophen","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"brimonidine-tartrate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE TARTRATE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"clonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Catapres-Tts-1","generic_name":"CLONIDINE","company_name":"Lavipharm","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"dorzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trusopt","generic_name":"DORZOLAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Carbonic Anhydrase Inhibitor","quality_score":51,"revenue":null,"mechanism":"Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye."},{"drug_id":"carbachol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miostat","generic_name":"CARBACHOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"carbachol","quality_score":48,"revenue":null,"mechanism":"Miostat works by mimicking the action of the neurotransmitter acetylcholine to increase the outflow of aqueous humor and reduce intraocular pressure."},{"drug_id":"levobunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betagan","generic_name":"LEVOBUNOLOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"brimonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"levobetaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaxon","generic_name":"LEVOBETAXOLOL","company_name":"Alcon Pharms Ltd","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"levobetaxolol","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aceclidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aceclidin","generic_name":"ACECLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"muscarinic receptors","drug_class":"aceclidine","quality_score":44,"revenue":null,"mechanism":"VIZZ, a pupil-selective miotic, contracts the iris sphincter muscle to improve vision by extending depth of focus."},{"drug_id":"acetylcholine","indication_name":"Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miochol-E","generic_name":"ACETYLCHOLINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Cholinergic Receptor Agonist","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Adjunct to incisional glaucoma surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"apraclonidine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iopidine","generic_name":"APRACLONIDINE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clonidin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clonidin","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"azopt","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azopt","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Neovascular glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"befunolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentos","generic_name":"BEFUNOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"befunolol","quality_score":null,"revenue":null,"mechanism":"Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure."},{"drug_id":"physostigmine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogmine","generic_name":"PHYSOSTIGMINE","company_name":"","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"physostigmine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"metipranolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Optipranolol","generic_name":"METIPRANOLOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"brinzolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azopt","generic_name":"BRINZOLAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"carbonic anhydrase II","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion."},{"drug_id":"xalatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xalatan","company_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epipen","generic_name":"epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epipen works by stimulating the alpha-1D adrenergic receptor to rapidly increase heart rate, blood pressure, and bronchodilation."},{"drug_id":"latanoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalatan","generic_name":"LATANOPROST","company_name":"Thea Pharma","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure."},{"drug_id":"dichlorphenamide","indication_name":"Angle-closure glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keveyis","generic_name":"DICHLORPHENAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye."},{"drug_id":"travoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Travatan","generic_name":"TRAVOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"dichlorphenamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keveyis","generic_name":"DICHLORPHENAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye."},{"drug_id":"dichlorphenamide","indication_name":"Secondary glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keveyis","generic_name":"DICHLORPHENAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye."},{"drug_id":"bimatoprost","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumigan","generic_name":"BIMATOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C3","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Lumigan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"methazolamide","indication_name":"Angle-closure glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neptazane","generic_name":"METHAZOLAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 3","drug_class":"methazolamide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neptazane","generic_name":"METHAZOLAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 3","drug_class":"methazolamide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methazolamide","indication_name":"Secondary glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neptazane","generic_name":"METHAZOLAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 3","drug_class":"methazolamide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Angle-closure glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Malignant glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Secondary glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"lidocaine-hydrochloride-and-epinephrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"Epinephrine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Epinephrine works by stimulating the alpha-1D adrenergic receptor to increase heart rate and blood pressure, and to constrict blood vessels."},{"drug_id":"carteolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocupress","generic_name":"CARTEOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"dipivefrine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dipivefrin","generic_name":"dipivefrine","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"Adrenergic Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pilocarpine","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pilocarpine","indication_name":"Primary Closed Angle Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"latanoprostene-bunod","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyzulta","generic_name":"LATANOPROSTENE BUNOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},{"drug_id":"netarsudil","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhopressa","generic_name":"NETARSUDIL","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"rho kinase","drug_class":"Rho Kinase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork."},{"drug_id":"betaxolol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betoptic","generic_name":"BETAXOLOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure."},{"drug_id":"echothiophate","indication_name":"Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phospholine Iodide","generic_name":"ECHOTHIOPHATE","company_name":"Fera Pharms Llc","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"echothiophate","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phospholine Iodide","generic_name":"ECHOTHIOPHATE","company_name":"Fera Pharms Llc","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"epinephrin","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epinephrin","company_name":"United States Naval Medical Center, San Diego","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"glanatec","indication_name":"Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glanatec","company_name":"Michael D. Straiko, MD","drug_phase":"phase_2","molecular_target":"Serine/threonine-protein kinase TAO3, 5'-AMP-activated protein kinase subunit gamma-1, Aurora kinase B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"travatan","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Travatan","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Primary Closed Angle Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"acetazolamide","indication_name":"Chronic simple (open-angle) glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"taxol","indication_name":"Open-angle glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"acetazolamide","indication_name":"Secondary glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Preoperative acute angle-closure glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"bupranolol","indication_name":"Glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupranol","generic_name":"BUPRANOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"Beta-2 adrenergic receptor","drug_class":"bupranolol","quality_score":31,"revenue":null,"mechanism":"Bupranol works by blocking the beta-2 adrenergic receptor, which helps to reduce the pressure in the eye and lower blood pressure."}],"pipeline":[],"offLabel":[],"totalMarketed":61,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03752840","title":"Village-Integrated Eye Worker Trial II","phase":"NA","overall_status":"RECRUITING","enrollment_count":60200,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04381611","title":"INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"Dr. Kaweh Mansouri","has_results":false},{"nct_id":"NCT03278587","title":"Village-Integrated Eye Worker Trial II - Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":16075,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07497815","title":"Artificial Intelligence-assisted Diagnosis in Ophthalmology","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Marisse Masis-Solano","has_results":false},{"nct_id":"NCT03268031","title":"Artificial Intelligence-assissted Glaucoma Evaluation","phase":"","overall_status":"COMPLETED","enrollment_count":10800,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04187157","title":"Association Between Light Spectrum and Survival After Cataract Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":10192,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT03682783","title":"Artificial Intelligence-assisted Glaucoma Screening (AIAGS)","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT00342342","title":"Family Studies of Eye Traits","phase":"","overall_status":"COMPLETED","enrollment_count":7370,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05992415","title":"Know Your Pressures NYC","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":7085,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05875090","title":"Glaucoma Portugal Screening Trial","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":6000,"lead_sponsor_name":"Centro Hospitalar Universitário Lisboa Norte","has_results":false},{"nct_id":"NCT06112431","title":"Eye Health Intervention Study in Upper Manhattan","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5840,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT07510087","title":"Glaucoma Related Quality of Life","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Marc Toeteberg-Harms","has_results":false},{"nct_id":"NCT00286637","title":"Novel Glaucoma Diagnostics","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Wills Eye","has_results":false},{"nct_id":"NCT07143851","title":"Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT06012058","title":"Glaucoma Screening With Artificial Intelligence","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3175,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06943599","title":"Strategies for Improving Linkage-to-Care After Eye Disease Screening","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03695224","title":"Matching Glaucoma With Impaired Cognition","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03491735","title":"Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Kasr El Aini Hospital","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01853085","title":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons","phase":"","overall_status":"COMPLETED","enrollment_count":1830,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06629649","title":"Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05394324","title":"A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products","phase":"","overall_status":"COMPLETED","enrollment_count":1674,"lead_sponsor_name":"Johnson & Johnson Surgical Vision, Inc.","has_results":false},{"nct_id":"NCT06434155","title":"Social History and Glaucoma Progression","phase":"","overall_status":"COMPLETED","enrollment_count":1584,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01999348","title":"A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1553,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06829810","title":"Long-term Outcomes of Glaucoma Surgery in a Real-life Setting: the Agora Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06213896","title":"Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi","has_results":false},{"nct_id":"NCT05703724","title":"Prevalence of Glaucoma in Belgium: a Multicenter National Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1418,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06226935","title":"Comparative Analysis of Glaucoma Screening Uptake Among First-Degree Relatives in Community-Based and Hospital-Based Approaches","phase":"","overall_status":"COMPLETED","enrollment_count":1304,"lead_sponsor_name":"Phrapokklao Hospital,Thailand","has_results":false},{"nct_id":"NCT04620876","title":"Bimodal and Coaxial High Resolution Ophtalmic Imaging","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT04454190","title":"Development and Validation of a Model to Predict Fast Progression in Glaucoma","phase":"","overall_status":"TERMINATED","enrollment_count":1152,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05710198","title":"Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Omikron Italia S.r.l.","has_results":false},{"nct_id":"NCT06485128","title":"Investigating Multimodally Endothelial Dysfunction in Ocular and Systemic Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06645964","title":"Evaluation of The Performance of Retinow AI Software","phase":"","overall_status":"COMPLETED","enrollment_count":915,"lead_sponsor_name":"Retinow Health Technologies and R&D Industry Joint Stock Company","has_results":false},{"nct_id":"NCT04328207","title":"Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits","phase":"NA","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT05563623","title":"The Beijing Angle Closure Progression Study","phase":"","overall_status":"RECRUITING","enrollment_count":825,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03159780","title":"Prevalence of Corneal Astigmatism Before Glaucoma Surgery in Chinese Patients With Primary Angle-closure Glaucoma","phase":"","overall_status":"COMPLETED","enrollment_count":808,"lead_sponsor_name":"Mingkai Lin","has_results":false},{"nct_id":"NCT01298700","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":806,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04967989","title":"Clarifying the Optimal Application of SLT Therapy Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":790,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT05269680","title":"STAR-LIFE: a Post-market Registry on MINIject","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"iSTAR Medical","has_results":false},{"nct_id":"NCT02571712","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT04271709","title":"Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":749,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT04723160","title":"Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph","phase":"","overall_status":"COMPLETED","enrollment_count":748,"lead_sponsor_name":"Visionary Intelligence Ltd.","has_results":false},{"nct_id":"NCT04426331","title":"Vouchers to Increase Uptake of Already Free Eye Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":739,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT01881425","title":"InnFocus MicroShunt Versus Trabeculectomy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"InnFocus Inc.","has_results":true},{"nct_id":"NCT02558400","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Aerie Pharmaceuticals","has_results":true},{"nct_id":"NCT03395535","title":"Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Moorfields Eye Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT04630808","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":696,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":false},{"nct_id":"NCT04445519","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":691,"lead_sponsor_name":"Nicox Ophthalmics, Inc.","has_results":true},{"nct_id":"NCT05397600","title":"Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"Laboratoires Thea","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}